A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Divarasib (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms Krascendo 2
- Sponsors Roche
- 03 Feb 2025 New trial record